Cytokinetics, Incorporated — 2013 Form 10-K Summary
Business context and reporting period
For the fiscal year ended December 31, 2013. Cytokinetics is a clinical-stage biopharmaceutical company developing small-molecule therapies that modulate muscle function. Its principal candidates were tirasemtiv (Phase IIb; ALS), CK-2127107 (Phase I; partnered with Astellas), and omecamtiv mecarbil (Phase II; partnered with Amgen). The company had no products approved for sale and no product-sales revenue.
Financial performance and liquidity
| Metric | 2013 | 2012 |
|---|---|---|
| Total revenue | $30.6 million | $7.6 million |
| Research and development expense | $49.5 million | $35.6 million |
| General and administrative expense | $15.1 million | $12.4 million |
| Operating loss | $33.9 million | $40.5 million |
| Net loss | $33.7 million | $40.4 million |
| Net loss per share | $1.24 | $2.30 |
| Net cash used in operating activities | $7.7 million | $33.4 million |
| Cash, cash equivalents and investments at year-end | $80.2 million | $74.0 million |
| Working capital at year-end | $52.6 million | $69.3 million |
Revenue increased by $23.1 million, largely from collaboration-related license revenue and research reimbursements, not product sales. Operating expenses were $64.5 million, producing an operating margin of approximately negative 111%. Operating cash use fell substantially from 2012, helped by $16.2 million of deferred revenue and increases in payables and accruals; it should not be read as a measure of recurring cash burn alone. The company reported $28.7 million of total liabilities, including deferred revenue, and no equipment-financing debt at year-end. Its accumulated deficit was $482.6 million.
Fourth-quarter revenue was $24.3 million and net income was $6.5 million, compared with revenue of $2.2 million and a net loss of $11.5 million in the fourth quarter of 2012. The 2013 quarter included substantial collaboration-license revenue recognition; it did not reflect commercial product sales or sustained profitability.
Material changes versus the prior comparable period
- Revenue rose to $30.6 million from $7.6 million, including $17.2 million of Amgen-related license revenue and $3.9 million recognized from Astellas’s upfront fee.
- R&D expense increased $13.8 million, principally from greater clinical and laboratory spending; skeletal-muscle program expense rose to $40.8 million from $24.9 million.
- Net loss narrowed by $6.7 million. Operating cash use declined by $25.7 million, while year-end cash and investments increased by $6.2 million.
- The company entered a worldwide collaboration with Astellas for CK-2127107 and expanded Amgen’s omecamtiv mecarbil collaboration to Japan. It received upfront payments of $16 million from Astellas and $15 million from Amgen; Amgen also bought $10 million of common stock.
Outlook, commentary, risks and unusual items
- For 2014, management projected R&D expense of $52–$55 million and G&A expense of $16–$18 million, both expected to increase. At December 31, 2013, management believed available cash and investments would fund operations for at least 12 months.
- After year-end, a February 2014 public offering generated approximately $37.4 million in net proceeds. The company also reported $2.4 million of net proceeds from January 2014 ATM sales. These are subsequent events, not 2013 operating cash flow.
- BENEFIT-ALS enrollment concluded at 711 patients, above the revised target, after a vendor programming error caused 58 patients assigned to tirasemtiv to receive placebo for part of the trial. The protocol was amended to preserve intended statistical power; the DSMB reported no safety concern from the error. Results were expected in April 2014. At least one confirmatory Phase III trial would likely be needed if results supported further development.
- In ATOMIC-AHF, omecamtiv mecarbil did not meet the primary dyspnea endpoint versus pooled placebo (p=0.33), although favorable dose-related trends were reported. Myocardial infarctions occurred in 2.3% of treated patients versus 1.0% on placebo; the filing reported no relationship between troponin increase and drug concentration. This safety observation merits scrutiny alongside the trial’s overall results.
- Key risks include ongoing losses and need for additional capital; uncertain clinical and regulatory outcomes; reliance on Amgen and Astellas for partnered programs; potential delays or failures at clinical vendors and manufacturers; and patent, competition, reimbursement, and market-acceptance risks. Collaboration milestone and royalty amounts are contingent, not assured.
- The company exited the accounting development stage in 2013 after collaboration agreements generated significant revenue. It completed a one-for-six reverse stock split in June 2013. No material legal proceedings were reported. The independent auditor gave unqualified opinions on the financial statements and internal control over financial reporting.
Most important facts for investors to verify
- Whether BENEFIT-ALS results support tirasemtiv’s efficacy and safety claims, and whether the protocol change and 58-patient assignment error affected interpretation.
- Whether the 2013 revenue increase and fourth-quarter profit are repeatable: collaboration accounting and upfront fees drove revenue, while product sales remained zero.
- Updated cash runway and expected cash burn after the February 2014 offering, including the cost and financing plan for potential tirasemtiv Phase III trials.
- Progress and safety findings from COSMIC-HF and subsequent omecamtiv mecarbil studies, including follow-up on the ATOMIC-AHF myocardial infarctions.
- Actual partner reimbursements, milestone eligibility and timing, and partners’ continuing development commitments; the stated potential payments depend on future events.
- Potential dilution: the filing reported approximately 7.7 million warrants outstanding at December 31, 2013, in addition to equity issuance and employee awards.